SMARCA2 and lung cancer: Hence, selective degradation of the SWI/SNF ATPase SMARCA2 by PROTACs YDR1 or YD54 was found to provide better sensitivity in SMARCA4 mutant xenografted lung cancer cells (Kotagiri et al., 2025).